C4 Therapeutics Inc
$ 2.81
15.64%
03 Dec - close price
- Market Cap 272,330,000 USD
- Current Price $ 2.81
- High / Low $ 2.84 / 2.41
- Stock P/E N/A
- Book Value 2.08
- EPS -1.67
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.60 %
- 52 Week High 5.10
- 52 Week Low 1.08
About
C4 Therapeutics, Inc. is an innovative biopharmaceutical company based in Watertown, Massachusetts, focused on developing advanced therapeutic candidates that selectively target and degrade disease-causing proteins. Specializing in oncology and neurodegenerative diseases, the company's proprietary dynamic protein degradation platform utilizes state-of-the-art biological mechanisms to offer groundbreaking treatment solutions for patients with significant unmet medical needs. Positioned as a leader in the biopharmaceutical industry, C4 Therapeutics is dedicated to transforming patient care by redefining treatment paradigms and improving clinical outcomes through its pioneering approaches.
Analyst Target Price
$11.86
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-30 | 2025-05-06 | 2025-02-20 | 2024-10-31 | 2024-08-01 | 2024-05-08 | 2024-02-22 | 2023-11-01 | 2023-08-08 | 2023-05-04 | 2023-02-23 |
| Reported EPS | -0.2954 | -0.37 | -0.37 | -0.49 | -0.35 | -0.26 | -0.41 | -0.7 | -0.52 | -0.73 | -0.71 | -0.77 |
| Estimated EPS | -0.4057 | -0.4 | -0.35 | -0.4504 | -0.38 | -0.37 | -0.35 | -0.68 | -0.66 | -0.69 | -0.75 | -0.74 |
| Surprise | 0.1103 | 0.03 | -0.02 | -0.0396 | 0.03 | 0.11 | -0.06 | -0.02 | 0.14 | -0.04 | 0.04 | -0.03 |
| Surprise Percentage | 27.1876% | 7.5% | -5.7143% | -8.7922% | 7.8947% | 29.7297% | -17.1429% | -2.9412% | 21.2121% | -5.7971% | 5.3333% | -4.0541% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CCCC
2025-11-02 11:25:42
C4 Therapeutics (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company focused on targeted protein degradation therapies, with its lead oncology candidate, CFT7455, showing promising early clinical trial results. Despite a significant stock decline, major collaborations with Merck and a strong cash position provide stability for the company. The article suggests C4T is a high-risk, high-reward investment given its early-stage pipeline, competitive landscape, and reliance on trial outcomes and partnership milestones.
2025-10-16 18:26:33
C4 Therapeutics' share price recently dropped 38% and is down 68% over the last year, leading to a low price-to-sales (P/S) ratio of 4.6x. This dip reflects concerns about the company's revenue growth, which, despite a recent 17% increase, has shrunk by 32% over three years and is forecast to grow slower than the industry. Analysts predict 31% annual revenue growth for C4 Therapeutics over the next three years, significantly less than the industry's projected 127% annual growth.
2025-10-16 12:14:42
C4 Therapeutics announced the pricing of a $125 million underwritten offering, leading to a pre-bell decline in its shares. The company, focused on targeted protein degradation science, continues to advance its clinical pipeline with product candidates like CFT7455 and CFT1946. This financial move comes amidst recent collaborations and clinical data presentations.
2025-10-16 12:13:40
C4 Therapeutics (CCCC) announced an underwritten public offering of common shares and pre-funded warrants to institutional investors, aiming to raise $125 million in gross proceeds, with a potential total of $349.7 million if all warrants are exercised. The company, a clinical-stage biopharmaceutical firm focusing on targeted protein degradation, plans to use the funds for clinical trials, R&D, and general corporate activities. Despite challenges in profitability and revenue growth, the offering is supported by existing investors and is expected to close around October 17.
2025-10-16 11:55:24
C4 Therapeutics (C4T) has announced the pricing of a $125 million underwritten offering of common stock and pre-funded warrants, with potential to earn up to an additional $225 million from warrant exercises. The proceeds are intended to fund clinical trials for cemsidomide in multiple myeloma, other research and development, and general corporate purposes. The offering was led by RA Capital Management with participation from existing shareholders.
2025-10-16 11:10:37
C4 Therapeutics, Inc. announced the pricing of a $125 million underwritten offering of common stock and pre-funded warrants, aiming to fund clinical trials for cemsidomide in multiple myeloma and other R&D activities. The offering includes Class A and Class B Warrants with potential to raise up to an additional $225 million if fully exercised. The financing round was led by RA Capital Management and included participation from other existing shareholders.
